GIA
CKPT

Gladstone Institutional Advisory’s Checkpoint Therapeutics CKPT Stock Holding History

Gladstone Institutional Advisory’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-61,399
Closed -$196K – 724
2024
Q4 		$196K Buy
61,399
+26,399
+75% +$89.5K 0.01% 674
2024
Q3 		$78.4K Buy
35,000
+20,500
+141% +$47.3K ﹤0.01% 671
2024
Q2 		$31.2K Buy
+14,500
New +$25.8K ﹤0.01% 655
2024
Q1 		– Sell
-10,000
Closed -$22.9K – 652
2023
Q4 		$22.9K Buy
+10,000
New +$21.8K ﹤0.01% 662

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Gladstone Institutional Advisory's CKPT Position: Q1 2025 in Review

Gladstone Institutional Advisory sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 61,399 shares — an estimated $196K sold.

Gladstone Institutional Advisory first reported a position in CKPT in Q4 2023 and held it in 4 quarters. The position peaked at $196K in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Gladstone Institutional Advisory reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 61,399 Checkpoint Therapeutics shares in Q1 2025, an estimated $196K.
  • Gladstone Institutional Advisory first reported a position in Checkpoint Therapeutics in Q4 2023 and held it in 4 quarters.
  • Gladstone Institutional Advisory's Checkpoint Therapeutics position peaked at $196K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2025, filed 15 May 2025.